Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1693-1698

  Miano, Maurizio ^a   Pistorio, Angela ^a   Putti, Maria C ^b   Dufour, Carlo ^a   Messina, Chiara ^b   Barisone, Elena ^c   Ziino, Ottavio ^d   Parasole, Rosanna ^e   Luciani, Matteo ^f   Lo Nigro, Luca ^g   Rossi, Giulio De ^f   Varotto, Stefania ^b   Bertorello, Nicoletta ^c   Petruzziello, Fara ^e   Calvillo, Michaela ^a   Micalizzi, Concetta ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^d Hospital G di Cristina   (Italy)

^e SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

Author keywords

Clofarabine; hematopoietic stem cell transplant; relapsed resistant pediatric leukemia

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTION; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ACUTE DISEASE; ADENINE NUCLEOTIDES; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; ETOPOSIDE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84861721732     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.663915     Document Type: Article

References (18)

1. C onter V, Aricó M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:255-264.
2. P ui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 200612;354:166-178.
3. P ession A, Rondelli R, Basso G, et a l. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols; AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP). Leukemia 2005;19:2043-2053.
4. Creutzig U, Zimmermann M, Ritter J, et a l. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-2042.
5. U derzo C, Dini G, Locatelli F, et al. Treatment of childhood acute lymphoblastic leukemia after the fi rst relapse: Curative strategies. Haematologica 2000;85(11 Suppl.):47-53.
6. Zwaan CM, Reinhardt D, Zimmerman M, et al. International BFMStudy Group on Paediatric AML Salvage treatment for children with refractory fi rst or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: Results of a phase II study. Br J Haematol 2010;148:768-776.
7. Sander A, Zimmermann M, Dworzak M, et a l. Consequent and intensifi ed relapse therapy improved survival in pediatric AML: Results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010;24:1422-1428.
8. Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed highrisk acute lymphoblastic leukemia. Leukemia 2008;22:2193-2200.
9. Zhenchuk A, Lotfi K, Juliusson G, et al. Mechanisms of anticancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78:1351-1359.
10. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784-789.
11. Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacologic study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-1173.
12. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacological study of clofarabine in patients with refractory or relapsed leukemia. Blood 2003;102:2379-2386.
13. J eha S, Gaynon P, Razzouk BI, et a l. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-1923.
14. Jeha S, Razzouk B, Rytting M, et a l. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009;27:4392-4397.
15. Hijiya N, Th omson B, Isakoff MS, et a l. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011;118:6043-6049.
16. Hijiya N, Gaynon P, Barry E, et a l. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination inpediatric patients with refractory or relapsed acute leukemia. Leukemia 2009;23:2259-2264.
17. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multi relapsed acute lymphoblastic leukemia. Br J Haematol 2009;147:371-378.
18. S tam RW, den Boer ML, Meijerink JP, et a l. Diff erential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270-1276.